Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study

Overview of attention for article published in Cancers, November 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 7,451 followers.

#PublicaSalutIB Desafiament a la sensibilitat endocrina del càncer de mama avançat HER2 negatiu amb la combinació d'eribulina i teràpia endocrina https://t.co/J87XoNyJ8K @SonLlatzer https://t.co/zLbtn5Pe3G https://t.co/51QlvRuwW2

#PublicaSalutIB Desafiament a la sensibilitat endocrina del càncer de mama avançat HER2 negatiu amb la combinació d'eribulina i teràpia endocrina https://t.co/sQaD8kUB5S @SonLlatzer https://t.co/8Pat1yJS8E https://t.co/lNhLmPQdfA

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.